Details

Evrin solution for injection 50mg / ml, 2ml No. 10

acute disorders of cerebral circulation (as part of complex therapy);

traumatic brain injury, the consequences of traumatic brain injury;

encephalopathy;

syndrome of vegetative (neurocirculatory) dystonia;

mild cognitive disorders of atherosclerotic genesis;

anxiety disorders in neurotic and neurosis-like states;

acute myocardial infarction (from the first day) as part of complex therapy;

primary open coal glaucoma of various stages, as part of complex therapy;

relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

acute intoxication with antipsychotic drugs;

acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Intramuscularly or intravenously (jet or drip). When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.

Doses are selected individually.

It is injected slowly over 5-7 minutes, drip - at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.

In acute disorders of cerebral circulation, it is used in complex therapy in the first 10-14 days - intravenous drip of 200-500 mg 2-4 times a day, then intramuscularly 200-250 mg 2-3 times a day for 2 weeks.

In case of traumatic brain injury and the consequences of trauma, the drug is used for 10-15 days by intravenous drip of 200-500 mg 2-4 times a day.
In case of discirculatory encephalopathy in the decompensation phase, the drug is used intravenously by jet or drip in a dose of 200-500 mg 1-2 times a day for 14 days. Then intramuscularly at 100-250 mg per day for the next two weeks.

For the course prevention of discirculatory encephalopathy, it is administered intramuscularly at a dose of 200-250 mg 2 times a day for 10-14 days.

With neurocirculatory dystonia, neurotic and neurosis-like conditions, the drug is administered intramuscularly at 50-400 mg per day for 14 days.

For mild cognitive impairments in elderly patients and with anxiety disorders, the drug is used intramuscularly at a dose of 100-300 mg per day for 14-30 days.

In acute myocardial infarction, as part of complex therapy, the drug is administered intravenously or intramuscularly for 14 days, against the background of standard therapy for myocardial infarction (including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as according to indications).

In the first 5 days, to achieve the maximum effect, the drug is administered intravenously, in the next 9 days the drug can be administered intramuscularly. Intravenous administration of the drug is carried out by drop infusion, slowly (to avoid side effects) for 30-90 minutes (in 100-150 ml of 0.9% sodium chloride solution or 5% dextrose (glucose) solution), if necessary, a slow jet injection of the drug is possible lasting at least 5 minutes. The drug is administered (intravenously or intramuscularly) 3 times a day every 8 hours. The daily dose is 6-9 mg / kg of body weight, a single dose is 2-3 mg / kg of body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

In case of open-angle glaucoma of various stages, as part of complex therapy , 100-300 mg per day are administered intramuscularly, 1-3 times a day for 14 days.

In case of alcohol withdrawal syndrome, the drug is administered intramuscularly or intravenously in a dose of 200-500 mg 2-3 times a day for 5-7 days.

In case of acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 200-500 mg per day for 7-14 days.

In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis), the drug is prescribed on the first day both in the preoperative and postoperative periods. The doses administered depend on the form and severity of the disease, the prevalence of the process, and the options for the clinical course. Cancellation of the drug should be made only after a stable positive clinical and laboratory effect.

In acute edematous (interstitial) pancreatitis, the drug is prescribed 200-500 mg 3 times a day, intravenously (in 0.9% sodium chloride solution) and intramuscularly.

Mild severity of necrotizing pancreatitis - 100-200 mg 3 times a day, intravenously drip (in 0.9% sodium chloride solution) and intramuscularly.

Average severity - 200 mg 3 times a day, intravenous drip (in 0.9% sodium chloride solution).

Severe course - at a dosage of 800 mg on the first day, with a two-fold administration regimen; then 200-500 mg 2 times a day with a gradual decrease in the daily dose.

Extremely severe course at an initial dosage of 800 mg per day until persistent relief of manifestations of pancreatogenic shock, after stabilization of the condition, 300-500 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.

1 ml of the drug contains:

Active substance: e tilmetilgidroksipiridina succinate - 50.0 mg

Excipients: Sodium disulfite - 0.47 mg, water for injection up to 1.0 ml

hypersensitivity to the drug;

acute hepatic and / or renal failure;

childhood;

pregnancy;

the period of breastfeeding - due to the lack of data on efficacy and safety.

Carefully

History of allergic diseases.

Trade name:

Evrin

Grouping name:

ethylmethylhydroxypyridine succinate

Dosage form:

solution for intravenous and intramuscular administration

Composition

1 ml of the drug contains:

Active ingredient: ethylmethylhydroxypyridine succinate - 50.0 mg

Excipients: Sodium disulfite - 0.47 mg, water for injection up to 1.0 ml

Description

Transparent colorless or slightly colored liquid.

Pharmacotherapeutic group:

antioxidant agent.

ATX code:

N07XX.

Pharmacological properties

Pharmacodynamics
Ethylmethylhydroxypyridine succinate belongs to the class of 3-hydroxypyridines, is an inhibitor of free radical processes, a membrane protector. It also has an antihypoxic effect, increases the body's resistance to stress.
The mechanism of action of ethylmethylhydroxypyridine succinate is due to its antioxidant and membrane-protective action. The drug inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the lipid-protein ratio, improves the structure and function of the cell membrane.
Ethylmethylhydroxypyridine succinate simulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, gamma-aminobutyric, acetylcholine), which enhances their ability to bind to ligandamines structure and improve their functional transport with ligandamines. transmission. Ethylmethylhydroxypyridine succinate increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energy-synthesizing functions of mitochondria.
Increases the body's resistance to the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebral circulation disorders, intoxication with ethanol and antipsychotic drugs).
In conditions of a critical decrease in coronary blood flow, it helps to preserve the structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes - phosphodiesterase, adenylate cyclase, acetylcholinesterase. Supports the activation of acetylcholinesterase that develops during acute ischemia. Supports the activation of aerobic glycolysis that develops during acute ischemia and promotes the restoration of mitochondrial redox processes under conditions of hypoxia, increases the synthesis of ATP and creatine phosphate. Provides the integrity of the morphological structures and physiological functions of the ischemic myocardium. Improves the clinical course of myocardial infarction, increases the effectiveness of therapy, reduces the incidence of arrhythmias and intracardiac conduction disorders.
It normalizes metabolic processes in the ischemic myocardium, increases the antianginal activity of nitrates, improves the rheological properties of blood, and reduces the consequences of reperfusion syndrome in acute coronary insufficiency.
Promotes the preservation of retinal ganglion cells and optic nerve fibers in progressive neuropathy, the causes of which are chronic ischemia and hypoxia. Improves the functional activity of the retina and optic nerve, increasing visual acuity.
Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.
Improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has a hypolipidemic effect by reducing the content of total cholesterol and low density lipoproteins.

Pharmacokinetics
Absorption
With a single and course administration, the maximum concentration (Cmax) in blood plasma is reached after 0.58 hours. When administered at a dose of 400-500 mg, Cmax in blood plasma is 3.5-4 ?g / ml.
Distribution
Rapidly distributed in organs and tissues. The average retention time of ethylmethylhydroxypyridine succinate in the body is 0.7-1.3 hours.
Metabolism
Metabolized in the liver by glucuronidation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - formed in the liver and, with the participation of alkaline phosphatase, decomposes into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, formed in large quantities and found in urine 1-2 days after administration; 3rd - excreted in large quantities in the urine; 4th and 5th - glucuron conjugates.
Excretion
It is excreted from blood plasma quickly and is practically undetectable after 4 hours in it. It is quickly excreted in the urine, mainly in the form of metabolites (50% in 12 hours), and in a small amount - unchanged (0.3% in 12 hours). The indicators of excretion in the urine of unchanged ethylmethylhydroxypyridine succinate and metabolites have individual variability.

Indications for use

acute disorders of cerebral circulation (as part of complex therapy);

traumatic brain injury, the consequences of traumatic brain injury;

encephalopathy;

syndrome of vegetative (neurocirculatory) dystonia;

mild cognitive disorders of atherosclerotic genesis;

anxiety disorders in neurotic and neurosis-like states;

acute myocardial infarction (from the first day) as part of complex therapy;

primary open coal glaucoma of various stages, as part of complex therapy;

relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

acute intoxication with antipsychotic drugs;

acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Contraindications

hypersensitivity to the drug;

acute hepatic and / or renal failure;

childhood;

pregnancy;

the period of breastfeeding - due to the lack of data on efficacy and safety.

Carefully

History of allergic diseases.

Application during pregnancy and during breastfeeding

Experimental studies have not revealed teratogenic, mutagenic, embryotoxic effects. There have been no adequate and strictly controlled clinical studies during pregnancy and lactation. The drug is contraindicated during pregnancy and during breastfeeding due to insufficient data on the effectiveness and safety of the drug during these periods.

Method of administration and dosage